BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Impact of Anti-citrullinated Protein Antibody Status on Treatment Response and Treatment Persistence in Participants With Rheumatoid Arthritis (RA) Who Are Treated With Abatacept or Tumor Necrosis Factor Inhibitors in Australia
- Conditions
- Rheumatoid Arthritis
- Interventions
- Other: Non-Interventional
- First Posted Date
- 2018-09-10
- Last Posted Date
- 2022-03-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 2052
- Registration Number
- NCT03663829
A Study to Observe the Onset of Immune-related Adverse Reactions in Patients With Non-surgical or Renal Cell Carcinoma (RCC) That Has Spread
- Conditions
- Kidney CancerRenal Cell Carcinoma
- Interventions
- Other: Non-Interventional
- First Posted Date
- 2018-09-10
- Last Posted Date
- 2022-02-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 81
- Registration Number
- NCT03663946
- Locations
- 🇯🇵
Local Institution, Tokyo, Japan
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
- Conditions
- Urinary Bladder NeoplasmsMuscle-Invasive Bladder Cancer
- Interventions
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 855
- Registration Number
- NCT03661320
- Locations
- 🇯🇵
Local Institution - 0171, Kita-gun, Kagawa, Japan
🇯🇵Local Institution - 0176, Hidaka-shi, Saitama, Japan
🇯🇵Local Institution - 0172, Shinjuku-ku, Tokyo, Japan
An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers
- Conditions
- Gastric CancerCancer of the StomachEsophagogastric Junction
- Interventions
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 274
- Registration Number
- NCT03662659
- Locations
- 🇩🇪
Local Institution - 0014, Frankfurt, Germany
🇺🇸Local Institution - 0040, Los Angeles, California, United States
🇺🇸Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2021-11-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 27
- Registration Number
- NCT03661632
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants
- First Posted Date
- 2018-09-06
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 131
- Registration Number
- NCT03660436
- Locations
- 🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States
Postmarketing Study of Empliciti in Korean Patients With Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- Other: Non-Interventional
- First Posted Date
- 2018-09-06
- Last Posted Date
- 2022-05-27
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT03660072
- Locations
- 🇰🇷
Local Institution, Seoul, Korea, Republic of
A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)
- First Posted Date
- 2018-09-04
- Last Posted Date
- 2025-02-20
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 139
- Registration Number
- NCT03656718
- Locations
- 🇺🇸
Local Institution - 0012, Eugene, Oregon, United States
🇺🇸Greenville Health System, Greenville, South Carolina, United States
🇺🇸Local Institution - 0011, Tyler, Texas, United States
Study to Determine if the Flu Vaccine Increases the Risk of Muscle Damage in Participants Taking Drugs That Block Certain Proteins Made by Some Types of Immune System Cells
- Conditions
- Cancer
- Interventions
- Other: Non-Interventional
- First Posted Date
- 2018-08-23
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1056
- Registration Number
- NCT03644498
- Locations
- 🇺🇸
Local Institution, Princeton, New Jersey, United States
An Investigational Study to Evaluate Experimental Medication BMS-986224 in Renally Impaired Participants
- First Posted Date
- 2018-08-17
- Last Posted Date
- 2020-02-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 50
- Registration Number
- NCT03634969
- Locations
- 🇺🇸
Prism Research, Saint Paul, Minnesota, United States
🇺🇸Clinical Pharmacology of Miami, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States